NR565 MIDTERM, WEEK 4 QUESTIONS WITH CORRECT ANSWERS 2025

NR565 MIDTERM, WEEK 4 QUESTIONS
WITH CORRECT ANSWERS 2025
whatNmakesNclopidogrelNuniqueNamongNotherNP2Y12Ninhibitors?N-NCORRECTNANSWERN-
reliesNonNcytochromeNP450NenzymeNtoNconvertNintoNactiveNmetaboliteN(CYP2C19)NthusNrequiringNthisNgen
eNtoNbeNpresentNtoNbeNanNeffectiveNdrugNinNclotNformation



AlternativesNtoNclopidogrelN-NCORRECTNANSWERN-
BrilintaN(ticagrelor)NorNEffientN(Prasugrel)NbecauseNtheyNareNnotNdependentNonNCYP2C19Ngenotype



NameNtheN4NmedicationsNthatNREQUIRENpharmacogeneticNtestingN-NCORRECTNANSWERN-
Cetuximab,Ntrastuzumab,Nmaraviroc,Ndasatinib



2NmedicationsNprescribedNtogetherNthatNareNhighlyNproteinNbound,NwhatNisNclinicalNoutcome?N-
NCORRECTNANSWERN-

TheNtwoNdrugsNcompeteNforNavailabilityNofNplasmaNproteinsNandNoneNorNtheNotherNbecomesNincreasinglyN
effective,NthinkNextraNmedicationNisNfloatingNaroundNasNitNcannotNbindNtoNplasmaNproteins.NWarfarinNisNhig
hlyNproteinNbound.



WhatNareasNofNhealthcareNmostNheavilyNintegrateNpharmacogeneticsNintoNclinicalNpractice?N-
NCORRECTNANSWERN-OncologyN&NcysticNfibrosisNpopulation



ThinkNHER2NwithNbreastNcancerNandNCFNhaveN2NdefectiveNCFTRNgenes



BarrierNinNunderstandingNracialNdifferencesNinNdrugNpharmacokineticsNwithNAmericanNIndianNorNAlaskanNN
atives?N-NCORRECTNANSWERN-LimitedNtoNnoNresearchNinNracialNconsiderations



PurposeNofNgeneticNtestingNwithNTamoxifen?N-NCORRECTNANSWERN-
ReduceNtheNriskNofNtherapeuticNfailureNasNvariationNofNCYP2D6NwillNnotNallowNforNactivationNandNconversio
nNtoNendoxifenNwhichNisNnecessaryNforNtreatingNestrogenNsensitiveNcancers.



LiverNandNKidneyNfunctionsNlabsNforNmonitoring?N-NCORRECTNANSWERN-
Creatinine,NBUN,NGFR,NAST,NALT,NBilirubin



DoseNofNpropranololNinNmigraineNreductionN-NCORRECTNANSWERN-20-80mgN3-4XNdaily

, increasesNlevelsNofNserotonin,NpreventsNbetaNreceptorNvasodilation

allowN4-6NweeksNtoNtrialNtreatment



FirstNconsiderationNinNselectingNmostNappropriateNbetaNblocker?N-NCORRECTNANSWERN-CardioNselectivity



PregnancyNCategoriesNBNvsNDNwithNbetaNblockersN-NCORRECTNANSWERN-AtenololN-ND

betaxolol,Nacebutolol,Nmetoprolol,Nnadolol,Nnebivolol,Ntiolol,NpropranololN-NC



WhereNareNbetaN2NreceptorsNlocatedNandNwhatNdoNtheyNdo?N-NCORRECTNANSWERN-
smoothNmuscleNofNeye,Narterioles,Nvenules,Nbronchioles,Nliver,Npancreas,NGI,NGU

StimulateNadneylylNcyclase,NincreaseNcAMP,NactivateNcardiacNG1



DrugNofNchoiceNforNHTNNwithNconcomitantNBPHN-NCORRECTNANSWERN-AlphaN1NadrenergicNantagonist



BetaNblockersNthatNrequireNdosageNadjustmentNinNpatientsNwithNrenalNimpairmentN-NCORRECTNANSWERN-
acebutolol,Natenolol,Nnadolol,NandNnebivolol



DosingNscheduleNofNdonepizilN-NCORRECTNANSWERN-5mgNnightlyNatNbedtime,NincreaseNatN4-
6NweekNintervals,NmaxNdoseNisN10NmgNdaily.



ElicitsNparasympatheticNresponseN-NCORRECTNANSWERN-Acetylcholine,NACh



SympatheticNnervousNsystemNresponsesNelicitedNby:N-NCORRECTNANSWERN-Epi,NNorepi,NDopa



FirstNlineNtreatmentsNforNHTNN-NCORRECTNANSWERN-CCB,NACEI,NARB,NorNthiazide

considerNcomorbidities



PatientsNwithNHTNNandNcomorbiditiesNofNessentialNtremor,Nmigraine,Narryhthmia,NCAD,NsymptomaticNHFN
withNreducedNEFNcanNbeNtreatedNwith?N-NCORRECTNANSWERN-betaNblocker